Director – Commercial Analytics - Obesity
About the job
- A doctorate degree, or a master's degree, or a bachelor's degree and 18 or more years of relevant experience.
- Substantial experience in commercial analytics, strategic insights, consulting, or related functions within pharmaceuticals, biotechnology, healthcare, or life sciences.
- Depth across product and brand strategy, launch analytics, sales force effectiveness, HCP and account analytics, payer and pricing analysis, commercial measurement, and executive insight translation.
- Experience supporting U.S. or global launches and growth assets in competitive, rapidly evolving therapeutic categories, ideally with high access and execution complexity.
- Strong understanding of U.S. pharmaceutical commercialization, selling models, field execution, stakeholder prioritization, and healthcare ecosystem dynamics.
- Knowledge of U.S. healthcare data ecosystems used for commercial decision-making, including sales, field activity, promotional engagement, claims, payer and pricing, and access-related data.
- Proven ability to translate complex analysis into recommendations that influence senior stakeholders and action planning.
- Experience partnering with technology, data science, and data engineering teams to develop scalable analytics products.
- Strong executive communication, stakeholder management, strategic thinking, and ability to balance practical delivery with high-quality analytical standards in a global environment.
- Set the commercial analytics agenda for obesity, including roadmap, delivery priorities, and senior decision forums.
- Turn product, field, account, payer and pricing, and U.S. stakeholder questions into pragmatic analytical plans and usable decision assets.
- Manage intake, prioritization, quality, governance, and execution while avoiding unnecessary process burden.
- Surface risks, options, and trade-offs early, backed by evidence and grounded in commercial reality.
- Raise the standard for reusable methods, continuously evolve how the function works, and build capabilities that improve over time as business needs change.
- Shape analysis that informs product strategy, commercialization readiness, lifecycle planning, and in-market action.
- Track the competitive landscape, treatment environment, access and pricing shifts, HCP behavior, and external signals, with strong attention to U.S. dynamics.
- Synthesize market, customer, competitive, and policy insights into clear assessments of launch readiness.
- Synthesize diverse internal and external data to identify opportunities, risks, and strategic priorities, and convert them into executive-ready narratives that clarify implications and decisions.
- Lead analysis for field sizing, customer segmentation, HCP and account engagement, and field execution.
- Develop national and sub-national insights that guide resource allocation, launch sequencing, and customer prioritization.
- Work across commercial, medical, market access, and product teams to evaluate strategic options and inform planning.
- Advance patient journey, market landscape, and stakeholder insights to inform priorities.
- Develop executive-ready insights that anticipate risks, highlight opportunities, and enable confident choices.
- Develop predictive models, scenario simulations, segmentation approaches, and driver analyses to answer high-value business questions.
- Apply quantitative techniques to estimate demand, assess adoption drivers, and evaluate the impact of market and competitive changes.
- Industrialize analytical methods through scalable, governed, and reusable solutions in partnership with data science and technology teams.
- Establish analytical standards, validation practices, and documentation that improve consistency, transparency, and confidence in outputs.
- Expand the use of automation, artificial intelligence, and experimentation to accelerate delivery and increase analytical rigor.
- Own the commercial analytics operating model for domain intake, prioritization, standards, delivery cadence, quality, and adoption.
- Standardize recurring work into reusable insight products, tools, and methods where scale creates value.
- Clarify how the function partners with forecasting, primary market research, and technology colleagues to deliver integrated work.
- Improve speed, consistency, and impact through pragmatic reuse, automation, and fit-for-purpose solutions.
- Build a connected capability recognized by the global obesity business for judgment, reliability, and business partnership.
- Build, develop, and lead a high-performing India-based team of analytics professionals.
- Create an environment of analytical excellence, accountability, curiosity, continuous learning, and ownership.
- Coach future leaders by expanding their commercial judgment, technical depth, strategic thinking, executive communication, and ability to influence across a global organization.
- Set clear goals, performance expectations, and development paths that link individual growth to organizational priorities.
- Help the team understand the business behind the analysis while establishing expectations for curiosity, ownership, and continuous learning.
- An advanced degree in Business, Analytics, Economics, Statistics, Engineering, Data Science, Life Sciences, Public Health, or a related field.
About the company
Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Get referred to Amgen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
- Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
- Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.
What critics are saying
- Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
- MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
- Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.
What makes Amgen unique
- It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
- Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
- Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Conference Attendance Budget
Company News
Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.
Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.
Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.
Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.
Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.